Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LIBERTY ASTHMA TREKIDS
- Sponsors Sanofi
- 02 Feb 2024 Status changed from not yet recruiting to recruiting.
- 08 Jan 2024 New trial record